Search
  • Our Company
    • Overview
    • Leadership
    • Board of Directors
  • Programs
    • Pipeline
    • IBD
    • NASH
    • Publications
  • Investors
    • Overview
    • News Releases
    • Events & Presentations
    • Stock Information
    • Corporate Governance
      • Governance Documents
      • Committee Composition
    • Financials & Filings
      • Sec Filings
    • Investor Resources
      • Email Alerts
      • IR Contact
      • FAQs
  • News
  • Careers
  • Contact
Publications
  • Our Company
    • Overview
    • Leadership
    • Board of Directors
  • Programs
    • Pipeline
    • IBD
    • NASH
    • Publications
  • Investors
    • Overview
    • News Releases
    • Events & Presentations
    • Stock Information
    • Corporate Governance
      • Governance Documents
      • Committee Composition
    • Financials & Filings
      • Sec Filings
    • Investor Resources
      • Email Alerts
      • IR Contact
      • FAQs
  • News
  • Careers
  • Contact
Publications

MET409, a Sustained FXR Agonist, Demonstrating Best-in-Class Potential for NASH

Back
Podium Presentation at Third Global NASH Congress, February 2020

poster thumbnail

Download PDF

© 2023 Metacrine   |   4225 Executive Square, Suite 600, San Diego, CA 92037
  • Our Company
    ▼
    • Overview
    • Leadership
    • Board of Directors
  • Programs
    ▼
    • Pipeline
    • IBD
    • NASH
    • Publications
  • Investors
    ▼
    • Overview
    • News Releases
    • Events & Presentations
    • Stock Information
    • Corporate Governance
      ▼
      • Governance Documents
      • Committee Composition
    • Financials & Filings
      ▼
      • Sec Filings
    • Investor Resources
      ▼
      • Email Alerts
      • IR Contact
      • FAQs
  • News
  • Careers
  • Contact